Updated:
Allarity Therapeutics
Allarity Therapeutics is a US-based company founded in 2004. It develops an oncology drug response predictor for personalized cancer therapy.
Overview
Allarity Therapeutics is a US-based company founded in 2004. It develops an oncology drug response predictor for personalized cancer therapy. The company has secured $909.3 million in total funding.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
Sector focus
Frequently asked questions
What does Allarity Therapeutics actually do?
Allarity develops oncology drug candidates and pairs them with a companion diagnostic called the Drug Response Predictor (DRP) platform. The diagnostic is designed to analyze a patient's tumor to predict whether they will respond to a specific therapy. The company has historically in-licensed drug candidates that larger pharmaceutical firms deprioritized, with the aim of demonstrating clinical utility in biomarker-selected populations.
Who runs Allarity Therapeutics?
As a public company, Allarity is led by a management team including a CEO, CFO, and CMO whose names are disclosed in SEC filings. No single family or founder controls a dominant equity stake in a family-office capacity. The shareholder base includes institutional investors and public market participants.
Does Allarity deploy capital into startups or venture funds?
No. Allarity does not operate as a venture capital firm, fund-of-funds, or corporate venture arm. It is an operating company that expends its capital on clinical trial costs, regulatory filings, and internal research activities. There is no disclosed co-investment platform or LP program.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: